Asset
ABBV-744
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03360006 | phase1 | terminated | 2018-03-16 | 2020-12-19 | AbbVie | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer |
| NCT04454658 | phase1 | active_not_recruiting | 2020-11-11 | 2027-01-01 | AbbVie | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis |
FDA applications (0)
This company has no applications containing this asset.